- 264%
-
272%
ONCQUER ASSIST PANEL
Identification of therapeutically relevant gene mutations for Cancer -
272%
ONCQUER CTC MONITORING (2 TEST ...
Identification of therapeutically relevant gene mutations for CancerONCQUER CTC MONITORING (2 TEST ...
Identification of therapeutically relevant gene mutations for Cancer -
272%
ONCQUER CTC MONITORING (3 TEST ...
Identification of therapeutically relevant gene mutations for CancerONCQUER CTC MONITORING (3 TEST ...
Identification of therapeutically relevant gene mutations for Cancer -
272%
ONCQUER CTC TESTING (1 TEST)
Identification of therapeutically relevant gene mutations for Cancer -
272%
Oncquer Germline Mutation Spec ...
Identification of therapeutically relevant gene mutations for CancerOncquer Germline Mutation Spec ...
Identification of therapeutically relevant gene mutations for Cancer -
264%
OncQuer TM Scout LB 56 Gene T ...
Identification of therapeutically relevant gene mutations for Myeloid cancerCancerOncQuer TM Scout LB 56 Gene T ...
Identification of therapeutically relevant gene mutations for Myeloid cancerCancer -
264%
OncQuer TM Scout LB EGFR Resi ...
Identification gene mutations leading to resistance to EGFR therapyOncQuer TM Scout LB EGFR Resi ...
Identification gene mutations leading to resistance to EGFR therapy -
264%
OncQuer TM Scout LB EGFR Resp ...
Identification gene mutations leading to sensitivity and resistance to EGFR therapyOncQuer TM Scout LB EGFR Resp ...
Identification gene mutations leading to sensitivity and resistance to EGFR therapy